Maintaining Investments in New Innovation Act

# HR 1672: Maintaining Investments in New Innovation Act - Summary **What the bill would do:** This bill would extend the time period before genetically targeted drugs can have their prices negotiated under Medicare's drug price negotiation program. Currently, most prescription drugs become eligible for Medicare price negotiations after 7 years on the market, while biologics (drugs made from living cells) wait 11 years. This bill would require genetically targeted drugs—medications designed to work for people with specific genetic characteristics—to wait the full 11 years before Medicare can negotiate their prices, the same timeframe as biologics. **Who it affects and why:** The bill primarily impacts Medicare beneficiaries (seniors and some disabled individuals), pharmaceutical companies that develop genetically targeted drugs, and the Medicare program itself. Supporters argue the longer exclusion period gives drug manufacturers more time to recoup development costs for these specialized medicines, potentially encouraging innovation in genetic medicine.

Critics might counter that it delays potential price reductions for patients and increases Medicare spending. **Current status:** The bill is currently in committee and has not yet been voted on by Congress. It was introduced by Representative Donald G. Davis (D-NC) in the 119th Congress.